Quick Answer
Processa Pharmaceuticals, Inc. reported Net Income Loss of -$13.56 million for the year ending 2025.
- Processa Pharmaceuticals, Inc. showed a decrease of -14.5% in Net Income Loss from 2024 to 2025.
- This data is from Processa Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$278.4 thousand | Q3 2017: -$711.6 thousand | Q4 2017: -$633.9 thousand | Q1 2018: -$1.10 million | Q2 2018: -$1.21 million | Q3 2018: -$852.8 thousand | Q1 2019: -$750.8 thousand | Q2 2019: -$969.1 thousand | Q3 2019: -$863.5 thousand | Q1 2020: -$874.3 thousand | Q2 2020: -$733.4 thousand | Q3 2020: -$3.07 million | Q1 2021: -$2.10 million | Q2 2021: -$3.16 million | Q3 2021: -$2.99 million | Q1 2022: -$3.23 million | Q2 2022: -$5.16 million | Q3 2022: -$6.02 million | Q1 2023: -$4.02 million | Q2 2023: -$2.61 million | Q3 2023: -$2.08 million | Q1 2024: -$2.73 million | Q2 2024: -$3.01 million | Q3 2024: -$3.38 million | Q1 2025: -$2.83 million | Q2 2025: -$3.93 million | Q3 2025: -$3.44 million.
- Over the full 14 years of available data (2012 to 2025), Processa Pharmaceuticals, Inc.'s Net Income Loss has declined by 455.8%.
- Historical annual values: Fiscal year 2025: -$13.56 million | Fiscal year 2024: -$11.85 million | Fiscal year 2023: -$11.12 million | Fiscal year 2022: -$27.42 million | Fiscal year 2021: -$11.43 million | Fiscal year 2020: -$14.41 million | Fiscal year 2019: -$3.36 million | Fiscal year 2018: -$3.77 million | Fiscal year 2017: -$1.86 million | Fiscal year 2016: -$1.92 million | Fiscal year 2015: -$3.35 million | Fiscal year 2014: -$4.53 million | Fiscal year 2013: -$3.07 million | Fiscal year 2012: -$2.44 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: